55456-41-2

Basic information

• Product Name: L-Tyrosine, O-methyl-, phenylmethyl ester
• CAS NO: 55456-41-2
• Molecular Formula: C17H19NO3
• Molecular Weight: 285.343
• Mol File: 55456-41-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: L-Tyrosine, O-methyl-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Tyrosine, O-methyl-, phenylmethyl ester(55456-41-2)
• EPA Substance Registry System: L-Tyrosine, O-methyl-, phenylmethyl ester(55456-41-2)

Safety Data

• Hazardous Substances Data: 55456-41-2(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 53267-93-9 O-methyl-N-tert-butoxycarbonyl-L-tyrosine 
• 137992-25-7 N-t-butoxycarbonyl-O-methyl-L-tyrosine benzyl ester 
• 6230-11-1 O-Methyltyrosine 
• 100-51-6 benzyl alcohol 
• 7635-29-2 O-methyl tyrosine 

Downstream Products

• 52219-97-3 2-Isocyanato-3-(p-methoxyphenyl)propionsaeurebenzylester 
• 1027174-70-4 (S)-2-[(1-tert-Butoxycarbonylamino-cyclopentanecarbonyl)-amino]-3-(4-methoxy-phenyl)-propionic acid benzyl ester 
• 960374-55-4 (S)-benzyl 2-((R)-2-((tert-butoxycarbonyl)amino)propanamido)-3-(4-methoxyphenyl)propanoate 
• 1427284-62-5 C₁₈H₁₇NO₃ 

Relevant articles and documents

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)

Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown. We reveal here our design of peptide epoxyketone-based selective low molecular mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors. Utilizing these and our previously disclosed low molecular mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model. These and additional findings toward optimized solubility led the design and selection of KZR-616 disclosed here and presently in clinical trials for treatment of rheumatic disease.

Compounds for enzyme inhibition

One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administer